Serina Therapeutics Inc. (SER)
5.28
0.53 (11.16%)
At close: Mar 28, 2025, 3:50 PM
5.30
0.38%
After-hours: Mar 28, 2025, 05:19 PM EDT
Company Description
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease.
The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy.
In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases.
Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Serina Therapeutics Inc.
| Country | United States |
| IPO Date | Jan 21, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Steven A. Ledger |
Contact Details
Address: 601 Genome Way Huntsville, Alabama United States | |
| Website | https://serinatherapeutics.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NYSE |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 81751A108 |
| ISIN Number | US81751A1088 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Steven A. Ledger | Chief Executive Officer & Director |
| Gregory S. Curhan | Chief Financial Officer |
| Dr. Balkrishan Gill Ph.D. | Executive Chairman |
| Dr. J. Milton Harris Ph.D. | Co-Founder, Director Emeritus & Chair of Scientific Advisory Board |
| Dr. Randall W. Moreadith M.D., Ph.D. | Chief Development Officer |